Tazobactam/piperacillin (TAZ/PIPC) is an antimicrobial drug agent with a broad spectrum of antibacterial activity and is recommended asˆrst-line therapy for hospital-acquired pneumonia, nursing-and healthcare-associated pneumonia, and other severe pneumonias. Nevertheless, in clinical settings, TAZ/PIPC is not fully eŠective in the treatment of pneumonia in the elderly. In the present study, we retrospectively investigated the e‹cacy of TAZ/PIPC for pneumonia in elderly patients and identiˆed factors that reduced its e‹cacy. Ninety-nine patients (mean age of 83.4 years and no signiˆcant diŠerence in the sex ratio) were included in the present study. The e‹cacy rate of TAZ/PIPC for pneumonia in elderly patients was 81.8％, which was approximately 7 to 10％ lower than that in domestic phase III trials. A multivariate analysis identiˆed the complications of chronic respiratory disease as a signiˆcant factor attenuating the therapeutic eŠects of TAZ/PIPC [odds ratio 4.050, 95％ conˆdence interval (CI) 1.008 16.271]. In conclusion, TAZ/ PIPC may not be su‹ciently eŠective for pneumonia in elderly patients with the complications of chronic respiratory disease as a background.
Data are the mean±S.D. or the number and percentage (％) of patients (n＝99). The numbers in parentheses are the range from the minimum to the maximum. e-GFR: estimated glomerularˆltration rate, WBC: white blood cell count, Hb: hemoglobin, CRP: c-reactive protein, NSAIDs: nonsteroidal anti-in‰ammatory drugs, PPIs: proton pump inhibitors, NHCAP: nursing-and healthcare-associated pneumonia, HAP: hospitalacquired pneumonia, CAP: community-acquired pneumonia, Medical device: gastrostomy tube, nasogastric tube, central venous catheter, or intubation. 
